Non Alcoholic Steatohepatitis Clinical Trial
Official title:
Vitamin E Versus Vitamin E Plus Pentoxiphyllin in Patients With Nonalcoholic Steatohepatitis: A Prospective Randomized Clinical Trial
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of hepatic pathology, ranging from simple steatosis, steatohepatitis, to cirrhosis. Nonalcoholic steatohepatitis (NASH) is a more advanced form of disease where steatosis is accompanied by hepatocyte injury as well as infiltration of inflammatory cells. Since, both vitamin E and PTX has been found to improve NASH when used alone, a combination of these two should be expected to give better results because of targeting two different pathogenetic mechanisms (cytokines amplification and oxidative stress) in NASH patients. This will be open labelled, prospective, randomized study. The diagnosis of NAFLD will be made on the basis of Ultrasonographic findings suggestive of fatty liver and presence of insulin resistance or features of metabolic syndrome. Subsequently histologic confirmation of the diagnosis of NASH will be made in all cases.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
| Completed |
NCT04573543 -
The Role of Immune Semaphorins in NAFLD
|
||
| Completed |
NCT01695083 -
Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients
|
||
| Not yet recruiting |
NCT05605158 -
Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis
|
Phase 3 | |
| Completed |
NCT01761370 -
Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH)
|
N/A | |
| Completed |
NCT03432377 -
Coffee Consumption and NASH in the French Population.
|
||
| Withdrawn |
NCT03864835 -
NASH-FITTER: Nonalcoholic Steatohepatitis Fitness Intervention Treatment Targeting Endothelial Dysfunction Reversal
|
N/A | |
| Completed |
NCT05357352 -
Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis
|
||
| Not yet recruiting |
NCT03803540 -
Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis
|
Phase 1 | |
| Completed |
NCT02395900 -
The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
|
Phase 2/Phase 3 | |
| Completed |
NCT01791959 -
The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05821010 -
Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis
|
Phase 2 | |
| Recruiting |
NCT03734510 -
The Effect of Supplementation of Flaxseed, Hesperidin, Flaxseed and Hesperidin Together in Non-alcoholic Fatty Liver Disease: A Randomized, Controlled Study
|
N/A | |
| Recruiting |
NCT02721264 -
Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.
|
N/A | |
| Terminated |
NCT03883607 -
Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Completed |
NCT03863574 -
Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis
|
Phase 2 | |
| Recruiting |
NCT03377153 -
The Effects of Hesperidin and Flaxseed on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
|
N/A | |
| Recruiting |
NCT03377140 -
The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
|
N/A | |
| Active, not recruiting |
NCT04669158 -
Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06176079 -
Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease
|